Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2311 to 2325 of 9128 results

  1. Camizestrant as an add-on to a first-line CDK4/6 inhibitor for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation [ID6535]

    Awaiting development Reference number: GID-TA11687 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Baloxavir marboxil for treating influenza in people 12 years and over at high risk of complications [ID3794]

    Awaiting development Reference number: GID-TA10683 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Filgotinib for treating axial spondyloarthritis [ID6594]

    In development Reference number: GID-TA11776 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management

    In development Reference number: GID-NG10435 Expected publication date:  16 February 2027

    NICE guideline
    In development

  5. Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

    In development Reference number: GID-TA11643 Expected publication date:  17 September 2026

    Technology appraisal guidance
    In development

  6. Elacestrant with everolimus for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6753]

    Awaiting development Reference number: GID-TA11973 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Enlicitide decanoate for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6656]

    Awaiting development Reference number: GID-TA11871 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]

    In development Reference number: GID-TA11519 Expected publication date:  30 September 2026

    Technology appraisal guidance
    In development

  9. Serplulimab with chemotherapy for neoadjuvant and adjuvant treatment of untreated gastric cancer [ID6760]

    Awaiting development Reference number: GID-TA11975 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Xanomeline tartrate–trospium chloride for treating schizophrenia ID6716

    In development Reference number: GID-TA11925 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Pembrolizumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]

    In development Reference number: GID-TA11694 Expected publication date:  10 February 2027

    Technology appraisal guidance
    In development

  12. Staged bilateral MRI-guided focused ultrasound thalamotomy for medication-refractory essential tremor

    In development Reference number: GID-HTG10860 Expected publication date:  17 December 2026

    HealthTech guidance
    In development

  13. Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707]

    Awaiting development Reference number: GID-TA11923 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Pritelivir (AIC-316) for Herpes simplex virus 2 infection (HSV-2) [12367]

    Awaiting development Reference number: GID-TA12465 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Topical tapinarof for treating mild to severe plaque psoriasis ID6712

    In development Reference number: GID-TA11951 Expected publication date: TBC

    Technology appraisal guidance
    In development